26 -2 (30) 2020 — Ismailov S.I., Saatov T.S., — CORONAVIRUS INFECTION COVID19 AND ENDOCRIN DISORDERS

CORONAVIRUS INFECTION COVID19 AND ENDOCRIN DISORDERS

Ismailov S.I. -Tashkent Pediatric Medical Institute, Institute of Biophysics and Biochemistry at National University of Uzbekistan.

Saatov T.S. -Tashkent Pediatric Medical Institute, Institute of Biophysics and Biochemistry at National University of Uzbekistan.

Shamansurova Z.M. -Tashkent Pediatric Medical Institute, Institute of Biophysics and Biochemistry at National University of Uzbekistan.

Resume,

The outbreak of the pandemic of a new infection caused by the SARS-CoV-2 coronavirus (COVID19) and the extent of its defeat over a short period of time is raised a number of questions both in the etiology and pathogenesis of the infection itself and its course when combined with other diseases, in particular endocrine disorders. The endocrine system impact the course of the pathological process, the manifestation of the symptoms and clinical future of diseases by regulating cellular metabolism. This literature review provides information on the structure, properties, mechanism of virus penetration into the body, the symptoms encountered and the clinical future of endocrine diseases, discusses new developments in the treatment and prevention of COVID19.

Key words: Coronavirus SARS-CoV-2, COVID-19, spark proteins, АСЕ2, CD147, glucocorticoids, Diabetes Mellitus, Thyroid and parathyroid glands diseases, Diabetes Insipidus.

First page

108

Last page

114

For citation: Ismailov S., Saatov T.S., Shamansurova Z.M. Coronavirus infection covid19 and endocrin disorders//New Day in Medicine 2(30)2020 108-114 https://cutt.ly/rcQvHiG

List of References

  1. Всемирная Организация Здравоохранения. Клиническое веде­ние тяжелой острой респираторной инфекции при подозре­нии на коронавирусную инфекцию COVID-19: Временные ре­комендации. / ВОЗ. 13 марта 2020 г https://apps.who.int/iris/ bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4- rus.pdf .
  2. Национальный медицинский исследовательский центр эндок­ринологии МЗ РФ. Эндокринопатии и COVID-19: Неотлож­ные состояния, их профилактика и лечение. https:// www.endocrincentr.ru/sites/default/files/all/news2020/ Institut%20Diabeta/COVID-19_enc2020-3.pdf
  3. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020 // Morbidity and Mortality Weekly Report 382 MMWR / April 3, 2020 / Vol. 69 / No. 13 US
  4. Coronavirus and parathyroid conditions FAQs https:// parathyroiduk.org/news/coronavirus-advice-for-people-with- hypoparathyroidism/
  5. Coutard, B. The spike glycoprotein of the new coronavirus 2019- nCoV contains a furin-like cleavage site absent in CoV of the same clade. / Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.G.; Decroly, E. // Antivir. Res.2020, 176, 104742.
  6. Danser A.H.J. Renin-Angiotensin System Blockers and the COVID- 19 Pandemic: At Present, There Is No Evidence to Abandon Renin-Angiotensin System Blockers. / Danser A.H.J., Epstein M, Batlle D. // Hypertension. 2020; 75:00-00. DOI: 10.1161/ HYPERTENSIONAHA.120.15082.
  7. Desailloud R. Viruses and thyroiditis: An update / Dessailloud R., Hober D. // Virol.J. 2009; 6;5
  8. Eguchi, S. Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology. / Eguchi, S., Kawai, T., Scalia, R., and Rizzo, V. (2018). // Hypertension 71, 804-810.
  9. Fang L. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? / Fang L, Karakiulakis G, Roth M. // Lancet Respir Med 2020; published online March 11. https://doi.org/10.1016/S2213-2600(20)30116-8.
  10. Ferrario CM. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin­convertin enzyme 2. / Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. // Circulation 2005; 111: 2605-10.
  11. Gentile S. COVID-19 Infection in italian people with diabetes: lessons learned for our future (an experience to be used), / Gentile S., Strollo F., Ceriello A. // Diabetes Research and Clinical Practice (2020), doi: https://doi.org/10.1016/ j.diabres.2020.108137
  12. Glowacka I, Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response. / Glowacka I, Bertram S, Mu?ller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Po?hlmann S. // JOURNAL OF VIROLOGY, May 2011, Vol. 85, No. 9 p. 4122­4134 doi:10.1128/JVI.02232-10.
  13. Gurwitz D. Angiotensin receptor blockers as tentative SARS? CoV?2 therapeutics. Drug Dev Res 2020; published online March 4. DOI:10.1002/ddr.21656.
  14. Guzzi PH. Master Regulator Analysis of the SARS-CoV-2/Human Interactome. / Guzzi PH., Mercatelli D, Ceraolo C and Giorgi FM. // J. Clin. Med. 2020, 9, 982; doi:10.3390/jcm9040982
  15. Han Y. COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster. / Han Y, Jiang M, Xia D, He L, Lv X, Liao X, Meng J. // Clin Immunol. 2020 Apr 8; 214:108413. doi: 10.1016/j.clim.2020.108413. [Epub ahead of print]
  16. Hirano T. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome / Hirano T, Murakami M. // Immunity (2020), https://doi.org/10.1016/j.immuni.2020.04.003
  17. Hoffmann, M. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. / Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Kr?ger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; Muller M.A., Drosten C., Pohlmann S. // Cell 2020.
  18. Huang, W. Modulation of CD147-induced matrix metalloproteinase activity: role of CD147 N-glycosylation. / Huang, W., Luo, W.J., Zhu, P., Tang, J., Yu, X.L., Cui, H.Y., Wang, B., Zhang, Y., Jiang, J.L., and Chen, Z. N. // Biochem. J. 449, 437­448
  19. Iacobellis G. COVID-19 and Diabetes: can DPP4 inhibition play a role? / Iacobellis G. // Diabetes Res Clin Pract. 2020;108125.
  20. Kacprzak-Bergman I. Influence of genetic factors on the susceptibility to HBV infection, its clinical pictures, and responsiveness to HBV vaccination / Kacprzak-Bergman I, Nowakowska B.// Arch Immunol Ther Exp., 2005, 53, 19-142 https://www.iitd.pan.wroc.pl/files/AITEFullText/7149.pdf

file

download